Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04969991 Terminated - Clinical trials for Coronavirus Disease 2019

Study of Varespladib in Patients Hospitalized With Severe COVID-19

STAIRS
Start date: June 30, 2021
Phase: Phase 2
Study type: Interventional

This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients hospitalized with severe COVID-19 caused by SARS-CoV-2.

NCT ID: NCT04969263 Completed - Clinical trials for Kidney Transplant Recipients

COVID-19 Protection After Transplant Pilot Study

CPAT
Start date: August 10, 2021
Phase: Phase 2
Study type: Interventional

Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.

NCT ID: NCT04969250 Completed - Covid19 Clinical Trials

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

Start date: August 25, 2021
Phase: Phase 4
Study type: Interventional

In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved sustained recovery, and who are still [TICO assignment] blinded and who are still within 28 to 90 days after initial TICO randomization, will be randomized in this 2x2 factorial design to one of four groups: (i) immediate versus 12 week deferral of first dose administration and also (ii) one dose only, versus two doses to be given 4 weeks apart of the Moderna mRNA-1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines). Choice of Moderna or Pfizer vaccine is determined based on availability at the site. The choice is individual, although participants vaccinated twice should receive the same type of vaccine for both injections. The primary objectives of this 2x2 factorial design are (i) to estimate the difference in neutralizing antibody (NAb) response to the mRNA vaccine from baseline to Week 48 among participants vaccinated early versus deferred, and (ii) to estimate the difference in NAb response to this vaccine among participants vaccinated once versus twice. The primary analyses will be carried out in participants randomized to placebo in TICO. Analyses will also be carried out for those who receive the investigational agent(s) studied in TICO. A key secondary objective is to ascertain the effect, if any, of SARS-CoV-2 monoclonal antibodies, and other interventions that have been studied in hospitalized COVID-19 subjects, on natural and vaccine-induced immunity. Participants will remain blinded to the interventions received in the ACTIV-3/TICO study, however allocation to the timing of vaccination and to one or two vaccinations in this (VATICO) study is not blinded.

NCT ID: NCT04969172 Active, not recruiting - COVID-19 Disease Clinical Trials

A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection

Start date: July 11, 2021
Phase: Phase 2
Study type: Interventional

A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study population will include patients with moderate or severe COVID-19 infection and laboratory markers predictive of the cytokine storm from the Corona department of each site, who have provided an informed consent. 155 patients will be randomized in a 2:1 ratio to receive either 1010 exosome particles (103 patients) or placebo (52 patients).The exosomes will be diluted in 4ml normal saline for inhalation, administered once daily (QD) for 5 days. Placebo (saline) will be prepared for inhalation and administered in the same manner as the exosomes.

NCT ID: NCT04967820 Completed - Burnout Clinical Trials

Burn-out Among Chinese Anaesthesiologist After COVID-19 Pandemic Peak and Its Protective Factor: a National Survey

Start date: August 1, 2021
Phase:
Study type: Observational

The investigators proposed a national representative survey to collect data of socio-demographic characteristics, level of exposure to COVID-19, depression,anxiety, ptsd, burnout and resilience of working anaesthesiologists across mainland China for the following purpose 1. Explore the current burn-out rate of Chinese anaesthesiologists and compared it with data acquired in 2015; 2. Explore the perceived covid-19 exposure of COVID-19 among Chinese anaesthesiologist. 3. Explore rate of burnout, anxiety, depression, PTSD symptoms experienced by the participants 4. Explore the protective psychosocial characteristics of burnout. (resilience) 5. See whether covid-19 exposure contribute to higher burn out rate.

NCT ID: NCT04967807 Active, not recruiting - SARS-CoV-2 Clinical Trials

Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)

MYOVAX
Start date: August 5, 2021
Phase: N/A
Study type: Interventional

The study will focus on cardiac blood and imaging biomarkers to facilitate early recognition of patients at risk for myocardial injury after COVID-19 vaccination. Ultimately, the intention is to identify patients at risk, reduce adverse events, and determine the need for longer-term follow-up in patients with myocardial injury after vaccination.

NCT ID: NCT04967768 Completed - Depression Clinical Trials

The Influence and Effects of the COVID-19 Pandemic on Orthopaedic Resident Training

Start date: December 30, 2020
Phase:
Study type: Observational

Orthopedic residents, like all other healthcare professionals, face unique challenges during the coronavirus disease 2019 (COVID-19). The rapid spread of COVID-19 has forced healthcare systems around the world to adapt. As in many other specialties, it has led to many changes in the training of orthopedic residents including restructuring of surgical training, a reduction in elective surgery cases, and re-assignment of residents to COVID-19-related clinical duties. As a result, the standard training curriculum has been interrupted and the number of surgical cases has decreased, limiting the ability of the residents to meet the range and number of patient follow-up and treatment requirements set by the Turkish Orthopedics and Traumatology Education Council (TOTEK). The already stressful work environment of orthopedic residents has become more stressful and anxious with the COVID-19 pandemic. There are no well-designed survey studies that have shown the impact of the COVID-19 pandemic on orthopedic resident education and well-being from the resident's perspective. Therefore, the purpose of this nationwide survey study was to document and analyze the effects of the COVID-19 pandemic on the real-life experiences of orthopedic residents in Turkey.

NCT ID: NCT04967742 Completed - COVID-19 Clinical Trials

A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

Start date: August 5, 2021
Phase: Phase 1
Study type: Interventional

This is an extension study to evaluate the safety, tolerability and immunogenicity of one booster dose of UB-612 COVID-19 vaccine in adults who completed two vaccinations of UB-612 vaccine 10, 30, and 100 μg in V-122 study.

NCT ID: NCT04967729 Completed - Covid19 Clinical Trials

COVID-19 and Lung Ultrasound Utility

Start date: June 10, 2021
Phase: N/A
Study type: Interventional

Ultrasounds are usually done by a specially trained health professional in the hospital or emergency department (ED) setting. Using a novel single-probe device, the ultrasound can be plugged into an iOS / Android device. The purpose of this research is to assess the usefulness of lung ultrasound imaging, performed by the patient in the home setting for the management of the COVID-19 disease using this novel highly-portable ultrasound.

NCT ID: NCT04967586 Completed - Covid19 Clinical Trials

Medical Students and Risk of COVID-19 Infection

Covid 19
Start date: December 1, 2020
Phase:
Study type: Observational

This study aims to estimate the prevalence of infected medical students with COVID-19 in the University of Jordan and to compare number of cases between students in clinical and basic years. In addition, this can provide insight into the awareness of infection control practices among students. Furthermore, to examine if hospital rotations increased risk of infection between clinical year medical students.